2009
Molecular Classification of Normal and Cancer Mammospheres.
Agarwal S, Camp R, Lannin D, Halligan K, Stern D, Tuck D, Harris L, Rimm D. Molecular Classification of Normal and Cancer Mammospheres. Cancer Research 2009, 69: 501-501. DOI: 10.1158/0008-5472.sabcs-09-501.Peer-Reviewed Original ResearchCancer stem cellsPrimary tumorBreast cancerTumor cellsStem cellsAbsence of CD24Breast cancer specimensHuman breast cancerFine-needle aspirationNormal breast tissueExpression of CD44Tumor tissue samplesPutative stem cell markersCD44-positive cellsKey protein markersEx vivo cultureStem cell markersNovel drug targetsSpecific therapyTreatment successNeedle aspirationCancer specimensMyoepithelial markersBT-20Positive cells
2003
Loss of Smad Signaling in Human Colorectal Cancer Is Associated with Advanced Disease and Poor Prognosis
Xie W, Rimm DL, Lin Y, Shih WJ, Reiss M. Loss of Smad Signaling in Human Colorectal Cancer Is Associated with Advanced Disease and Poor Prognosis. The Cancer Journal 2003, 9: 302-312. PMID: 12967141, DOI: 10.1097/00130404-200307000-00013.Peer-Reviewed Original ResearchConceptsColorectal cancerHuman colorectal cancerAdvanced diseasePoor prognosisHuman colorectal cancer specimensAdvanced stage diseasePresence of lymphLymph node metastasisColorectal cancer specimensShorter overall survivalClinical outcome informationOverall survivalNode metastasisClinical behaviorReceptor defectCancer specimensTissue microarrayAnimal studiesCancerSmad signalingOutcome informationPhosphorylated Smad2DiseaseSmad activationSmad2
2002
Subjective Differences in Outcome Are Seen as a Function of the Immunohistochemical Method Used on a Colorectal Cancer Tissue Microarray
Chung GG, Kielhorn EP, Rimm DL. Subjective Differences in Outcome Are Seen as a Function of the Immunohistochemical Method Used on a Colorectal Cancer Tissue Microarray. Clinical Colorectal Cancer 2002, 1: 237-242. PMID: 12450422, DOI: 10.3816/ccc.2002.n.005.Peer-Reviewed Original ResearchConceptsTissue microarrayTissue sectionsColorectal cancer tissue microarraySemiquantitative grading systemColorectal cancer specimensCancer tissue microarrayPatient outcomesLarge cohortSubjective assessmentCancer specimensImmunohistochemical methodsGrading systemNuclear stainingPathology literatureProtein expressionTissue samplesCell preparationsExpression levelsBeta-catenin antibodyCurrent standardImmunohistochemistryCohortOutcomesApparent increaseExpression
2001
Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis.
Chung GG, Provost E, Kielhorn EP, Charette LA, Smith BL, Rimm DL. Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. Clinical Cancer Research 2001, 7: 4013-20. PMID: 11751495.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBeta CateninCadherinsCell LineCell NucleusColorectal NeoplasmsCytoplasmCytoskeletal ProteinsDogsGene Expression Regulation, NeoplasticHumansImmunohistochemistryNeoplasm StagingOligonucleotide Array Sequence AnalysisPhosphoproteinsPrognosisProportional Hazards ModelsRecombinant ProteinsReproducibility of ResultsSurvival RateTrans-ActivatorsTransfectionTreatment OutcomeConceptsOverall survivalNuclear expressionColorectal cancerSeries of patientsColorectal cancer specimensTissue microarray analysisMajority of cancersBetter prognosisClinical outcomesClinicopathological factorsImproved survivalCancer specimensTissue microarrayImmunohistochemical analysisMembranous stainingColorectal tumorigenesisCytoplasmic stainingMultivariate analysisSignificant associationCancerAdenomatous polyposis coli (APC) geneNuclear stainingBeta-catenin overexpressionOnly stageSurvival